CD274 and neoplasm: The NCCN Guidelines Version 4.2025 advocate pembrolizumab (specifically for tumor mutational burden high, PD-L1-positive, or microsatellite instability-high (MSI-H)/mismatch repair deficiency tumor profiles) as the principal option for second-line or subsequent therapies.